Barclays
AQST icon

Barclays’s Aquestive Therapeutics AQST Stock Holding History

Barclays’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.87M Buy
1,051,639
+54,974
+6% +$244K ﹤0.01% 2059
2026
Q2 		$4.15M Buy
996,665
+197,502
+25% +$831K ﹤0.01% 1943
2026
Q1 		$3.32M Buy
799,163
+458,356
+134% +$1.86M ﹤0.01% 2061
2025
Q4 		$2.2M Buy
340,807
+209,049
+159% +$1.3M ﹤0.01% 2866
2025
Q3 		$737K Sell
131,758
-22,070
-14% -$95.4K ﹤0.01% 3562
2025
Q2 		$509K Buy
153,828
+70,871
+85% +$203K ﹤0.01% 3751
2025
Q1 		$241K Sell
82,957
-35,754
-30% -$108K ﹤0.01% 3939
2024
Q4 		$423K Buy
118,711
+19,399
+20% +$89.5K ﹤0.01% 3932
2024
Q3 		$495K Buy
99,312
+73,542
+285% +$286K ﹤0.01% 3780
2024
Q2 		$67K Buy
+25,770
New +$86.1K ﹤0.01% 4089
2023
Q4 		– Sell
-7,144
Closed -$10.9K – 5221
2023
Q3 		$10.9K Buy
+7,144
New +$12.3K ﹤0.01% 4289
2022
Q2 		– Sell
-24,829
Closed -$65K – 5007
2022
Q1 		$65K Hold
24,829
– – ﹤0.01% 3992
2021
Q4 		$97K Sell
24,829
-3,097
-11% -$15.5K ﹤0.01% 3738
2021
Q3 		$122K Sell
27,926
-3,456
-11% -$13.6K ﹤0.01% 3829
2021
Q2 		$125K Buy
31,382
+14,770
+89% +$59K ﹤0.01% 3755
2021
Q1 		$86K Buy
16,612
+10,197
+159% +$54.2K ﹤0.01% 4063
2020
Q4 		$34K Sell
6,415
-2,665
-29% -$16K ﹤0.01% 4554
2020
Q3 		$43K Sell
9,080
-23,262
-72% -$152K ﹤0.01% 4664
2020
Q2 		$156K Buy
+32,342
New +$149K ﹤0.01% 4246
2020
Q1 		– Sell
-159
Closed -$1K – 6118
2019
Q4 		$1K Sell
159
-652
-80% -$3.39K ﹤0.01% 6264
2019
Q3 		$2K Buy
811
+391
+93% +$1.46K ﹤0.01% 6537
2019
Q2 		$2K Sell
420
-5,441
-93% -$27.9K ﹤0.01% 6787
2019
Q1 		$40K Buy
+5,861
New +$41.1K ﹤0.01% 6023
2018
Q4 		– Sell
-1,956
Closed -$34K – 6907
2018
Q3 		$34K Buy
+1,956
New +$32.2K ﹤0.01% 6262

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Barclays's AQST Position: Q3 2026 in Review

Barclays increased its Aquestive Therapeutics (AQST) stake by 5.5% in Q3 2026, buying an estimated $244K and bringing the position to 1,051,639 shares worth $4.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2059.

Barclays first reported a position in AQST in Q3 2018 and has held it in 24 quarters since. 68 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Barclays held 1,051,639 shares of Aquestive Therapeutics worth $4.87M as of Q3 2026.
  • Barclays bought 54,974 Aquestive Therapeutics shares in Q3 2026, an estimated $244K.
  • Aquestive Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2059 holding.
  • Barclays first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 24 quarters since.
  • 68 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.